The S&P 500 has had one heck of a bull run over the last 7.5 years, up 259.3% since bottoming on March 3, 2009. So not surprisingly the market’s PE ratio of 24.5, 67.3% above its median historical norm of 14.6, has a lot of people calling a market top and advising selling stocks and moving to cash.
While this certainly sounds like a nice idea in theory, the simple fact is that market timing, (as a future article will explain), simply doesn’t work for the vast majority of investors. So rather than throw up your hands and let slowly accelerating inflation eat away at your money’s buying power, here’s a surprising, simple, but true fact that can help you become an investing legend.
On Wall Street, no matter how crazy expensive the market may be, SOMETHING is always on sale.
Today’s obvious example is oil stocks, which have been hammered by the worst oil crash in over 50 years. But energy is far from the only hated industry. Biotech companies, including some great dividend growth names such as Gilead Sciences, (GILD), Teva Pharmaceuticals (TEVA), AbbVie (ABBV), and Amgen (AMGN) have all been hammered hard in the past year, partially due to overblown concerns about whether or not Hillary Clinton is going to impose price controls on the industry.
In reality, her proposals, A aren’t likely to pass a gridlocked Congress, B, don’t target the majority of the these companies’ cash cows, and C. the biotech industry has adapted to a plethora of mandatory price discounts on drugs sold to Medicaid patients, hospitals in underserved communities, and Medicare patients who fall into the “donut hole”. These mandatory discounts, ie price caps, can be as much as 50%.